

浏览全部资源
扫码关注微信
河南省中医院,河南中医药大学 第二附属医院,郑州 450002
Received:10 March 2021,
Published Online:12 May 2021,
Published:05 July 2021
移动端阅览
陈凯旋,张龙江,李鹏超等.加味增液汤治疗气阴两虚型慢传输型便秘的疗效评价及对胃肠功能的影响[J].中国实验方剂学杂志,2021,27(13):72-77.
CHEN Kai-xuan,ZHANG Long-jiang,LI Peng-chao,et al.Clinical Efficacy of Modified Zengyetang Against Slow Transit Constipation Due to Qi-Yin Deficiency and Its Effect on Gastrointestinal Function[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(13):72-77.
陈凯旋,张龙江,李鹏超等.加味增液汤治疗气阴两虚型慢传输型便秘的疗效评价及对胃肠功能的影响[J].中国实验方剂学杂志,2021,27(13):72-77. DOI: 10.13422/j.cnki.syfjx.20211392.
CHEN Kai-xuan,ZHANG Long-jiang,LI Peng-chao,et al.Clinical Efficacy of Modified Zengyetang Against Slow Transit Constipation Due to Qi-Yin Deficiency and Its Effect on Gastrointestinal Function[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(13):72-77. DOI: 10.13422/j.cnki.syfjx.20211392.
目的
2
观察加味增液汤治疗气阴两虚型慢传输型便秘(STC)的临床疗效及对胃肠功能的影响。
方法
2
将130例患者随机按数字表法分为对照组65例(脱落、失访6例,完成59例)和治疗组65例(脱落、失访3例,完成62例)。对照组口服枸橼酸莫沙必利分散片,5 mg/次,3次/d。治疗组口服加味增液汤,1剂/d。两组疗程均为4周。记录治疗前后便秘主要症状评分、便秘患者症状自评量表(PAC-SYM)评分、中医证候评分、结肠传输试验情况及胃动素(MTL),血管活性肠肽(VIP),P物质(SP)水平,并记录治疗期间患者平均每周自发完全排便次数(SCBM)及其复发情况。
结果
2
治疗后治疗组临床疗效(95.16%)明显高于对照组(81.36%)(
χ
2
=5.6314,
P
<
0.05);治疗组复发率(30.65%)显著低于对照组(57.63%)(
χ
2
=8.941 1,
P
<
0.01);治疗后治疗组患者便秘主要症状评分低于对照组(
P
<
0.01),治疗后治疗组患者PAC-SYM量表3个维度评分及总评分均低于对照组(
P
<
0.01),治疗后治疗组患者中医证候评分低于对照组(
P
<
0.01),治疗后治疗组患者在24,48,72 h 残留标志物比例均低于对照组(
P
<
0.01),治疗组患者在治疗后2,3,4周的SCBM均高于对照组(
P
<
0.01),且治疗后与对照组比较,治疗组患者MTL,SP水平显著升高,VIP水平显著降低(
P
<
0.01)。
结论
2
采用加味增液汤治疗气阴两虚型STC患者可有效缓解其临床症状,调节胃肠激素分泌,增加SCBM,提高结肠传输功能,且复发率低。
Objective
2
To observe the clinical effect of modified Zengyetang in treating slow transit constipation (STC) due to Qi-Yin deficiency and its effect on gastrointestinal function.
Method
2
One hundred and thirty eligible patients were randomly divided into a control group (
n
=65, 6 cases dropped out or were lost to follow-up and 59 completed the trial) and a treatment group (
n
=65, 3 cases dropped out or were lost to follow-up and 62 completed the trial). Patients in the control group received oral mosapride citrate dispersible tablets, 5 mg per time, three times per day, while those in the treatment group were treated with modified Zengye Tang, one bag per day, for four successive weeks. The main symptom constipation, the Patient Assessment of Constipation Symptoms (PAC-SYM), and traditional Chinese medicine (TCM) syndrome scores, colonic transit, as well as motilin (MTL), vasoactive intestinal peptide (VIP), and substance P (SP) levels before and after treatment were recorded, together with the frequency of spontaneous complete bowel movements (SCBMs) per week and STC recurrence during treatment.
Result
2
The clinical efficacy (95.16%) of the treatment group was higher than that (81.36%) of the control group (
χ
2
=5.631 4,
P
<
0.05), whereas the recurrence rate (30.65%) of the treatment group was significantly lower than that (57.63%) of the control group (
χ
2
=8.941 1,
P
<
0.01). After treatment, the main symptom constipation, three sub-scale and total PAC-SYM, and TCM syndrome scores in the treatment group were obviously decreased as compared with those in the control group (
P
<
0.01). The proportions of residual markers at 24, 48, and 72 h in the treatment group declined in contrast to those in the control group (
P
<
0.01). The frequency of SCBMs per week in the 2
nd
, 3
rd
, and 4
th
weeks of the treatment group was higher than that in the control group (
P
<
0.01). Compared with the control group after treatment, the treatment group exhibited significantly elevated MTL and SP but lowered VIP (
P
<
0.01).
Conclusion
2
Modified Zengyetang relieves the clinical symptoms, regulates gastrointestinal hormone secretion, increases the frequency of SCBMs, enhances colonic transit, and decreases the recurrence of patients with STC due to Qi-Yin deficiency.
FU T , ZHAO S , LI F , et al . Single-incision laparoscopic subtotal colectomy with cecorectal anastomosis for slow transit constipation [J]. Tech Coloproctol , 2016 , 20 ( 2 ): 135 - 137 .
刘春强 , 王梦迪 , 黄业保 , 等 . 针刺壮医脐内环穴治疗慢传输型便秘(气秘型)临床观察 [J]. 广西中医药 , 2019 , 42 ( 6 ): 26 - 28 .
王满 , 刘妮妮 , 田萍 , 等 . 白术七物颗粒对结肠慢传输型便秘小鼠胃肠功能的影响及机制 [J]. 世界中医药 , 2018 , 13 ( 8 ): 1979 - 1983 .
方秀才 , 刘宝华 . 慢性便秘 [M]. 北京 : 人民卫生出版社 , 2015 : 425 - 440 .
杨颖 , 余清华 , 王宇 , 等 . 济川煎对慢传输型便秘大鼠的水通道蛋白影响 [J]. 中药药理与临床 , 2019 , 35 ( 6 ): 15 - 19 .
李冀 , 王景杰 , 张超 , 等 . 番泻苷A对慢传输型便秘大鼠肠动力的影响 [J]. 世界中医药 , 2018 , 13 ( 8 ): 1984 - 1987 .
何玉清 . 莫沙必利配合穴位埋线治疗结肠慢传输型便秘50例疗效观察 [J]. 中国肛肠病杂志 , 2020 , 40 ( 1 ): 44 - 45 .
吴双 . 开通玄府针刺法联合电针刺激骶神经治疗慢传输型便秘临床观察 [J]. 实用中医药杂志 , 2019 , 35 ( 11 ): 1378 - 1380 .
张慧田 , 马兴婷 . 增液承气汤联合粪菌移植对慢性功能性便秘的疗效 [J]. 中国中西医结合消化杂志 , 2021 , 29 ( 1 ): 53 - 57 .
毕继发 . 增液汤加减方治疗慢传输型便秘(气阴两虚型)的临床观察 [D]. 沈阳 : 辽宁中医药大学 , 2020 .
马雪巍 , 刘传佳 , 唐学贵 . 增液汤对慢传输型便秘大鼠结肠AQP9的影响及血清中5-HT的表达变化 [J]. 中华中医药学刊 , 2020 , 38 ( 4 ): 125 - 129,269 .
马雪巍 , 刘传佳 , 唐学贵 . 增液汤对慢传输型便秘大鼠结肠AQP3和血清中NOS的影响 [J]. 中华中医药学刊 , 2020 , 38 ( 5 ):64-68, 270 - 271 .
中华医学会外科学分会结直肠肛门外科学组 , 中华医学会消化病学分会胃肠动力学组 . 中国慢性便秘诊治指南(2013,武汉) [J]. 胃肠病学 , 2013 , 18 ( 10 ): 605 - 612 .
中华中医药学会脾胃病分会 . 便秘中医诊疗专家共识意见(2017) [J]. 中医杂志 , 2017 , 58 ( 15 ): 1345 - 1350 .
TACK J , TALLEY N J . Functional dyspepsia symptoms definitions and validity of the Rome Ⅲ criteria [J]. Nat Rev Gastroenterol Hepatol , 2013 , 10 ( 3 ): 134 - 141 .
国家药品监督管理局 . 中药新药临床研究指导原则 [M]. 北京 : 中国医药科技出版社 , 2002 : 378 - 385 .
宋玉磊 , 林征 , 柏亚妹 . 功能性便秘疗效评估指标的现状与评价 [J]. 中国实用内科杂志 , 2016 , 36 ( 9 ): 813 - 816 .
黄璇 . 慢传输型便秘与出口梗阻型便秘的中医证型分布研究 [J]. 内蒙古中医药 , 2016 , 35 ( 2 ): 159 - 160 .
刘丽兵 , 邓秋林 , 汤国辉 , 等 . 补气增液汤对慢传输型便秘大鼠肠道功能、肠神经递质及Cajal间质细胞的影响 [J]. 东南大学学报:医学版 , 2019 , 38 ( 3 ): 433 - 438 .
范亚楠 , 王佳 , 贾天柱 , 等 . 肉苁蓉炮制前后对大鼠肠神经递质及VIP、SP表达的影响 [J]. 医学研究杂志 , 2017 , 46 ( 6 ): 51 - 55 .
李明 , 王建民 , 杨玲玲 , 等 . 慢传输型便秘中医证型与血管活性肠肽和P物质关系 [J]. 安徽中医药大学学报 , 2014 , 33 ( 5 ): 21 - 23 .
李德意 , 辛学知 , 庞雪 . 慢传输型便秘神经递质改变的病机研究进展 [J]. 中国肛肠病杂志 , 2018 , 38 ( 9 ): 66 - 68 .
0
Views
21
下载量
5
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621